Secondary resistance to tolvaptan in two patients with SIAD due to small cell lung cancer

Eur J Clin Pharmacol. 2018 Feb;74(2):245-246. doi: 10.1007/s00228-017-2363-7. Epub 2017 Nov 16.

Authors

A Garrahy¹, A M Hannon², H M Zia-Ul-Hussnain², D J Williams³, C J Thompson²

Affiliations

¹ Academic Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Dublin, Ireland. aoifegarrahy@beaumont.ie.
² Academic Department of Endocrinology, Beaumont Hospital and RCSI Medical School, Dublin, Ireland.
³ Department of Geriatric and Stroke Medicine, Beaumont Hospital and RCSI Medical School, Dublin, Ireland.

PMID: 29147803
DOI: 10.1007/s00228-017-2363-7

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antidiuretic Hormone Receptor Antagonists / pharmacology*
Antidiuretic Hormone Receptor Antagonists / therapeutic use
Benzazepines / pharmacology*
Benzazepines / therapeutic use
Drug Resistance
Fatal Outcome
Female
Genetic Diseases, X-Linked / diagnosis
Genetic Diseases, X-Linked / drug therapy*
Genetic Diseases, X-Linked / etiology
Genetic Diseases, X-Linked / urine
Humans
Inappropriate ADH Syndrome / diagnosis
Inappropriate ADH Syndrome / drug therapy*
Inappropriate ADH Syndrome / etiology
Inappropriate ADH Syndrome / urine
Lung Neoplasms / blood
Lung Neoplasms / complications*
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / urine
Male
Middle Aged
Small Cell Lung Carcinoma / blood
Small Cell Lung Carcinoma / complications*
Small Cell Lung Carcinoma / diagnostic imaging
Small Cell Lung Carcinoma / urine
Sodium / blood
Tolvaptan
Vasopressins / blood

Substances

Antidiuretic Hormone Receptor Antagonists
Benzazepines
Vasopressins
Tolvaptan
Sodium

Supplementary concepts

Nephrogenic Syndrome of Inappropriate Antidiuresis